MEPION

[Medical Newspaper/Daily Bosa = Reporter Kim Jung-il] Hyundai Pharmaceutical announced on the 21st that it has signed an exclusive domestic supply contract with Mepion for the anti-adhesion cover material 'Lapafilm^®', a third-grade medical device. With this contract, Hyundai Pharmaceutical is in charge of domestic marketing, distribution and sales.

From left, MEPION CEO Nam Joong-hyuk and Hyundai Pharmaceutical CEO Lee Sang-joon. 

"Lapafilm^®" is an innovative medical device that overcomes the limitations of existing anti-adhesive agents, and is an anti-adhesive film optimized for minimally invasive surgery with excellent physical properties, moisture resistance, and non-adhesive properties between products. Since it is made of biocompatible material, it has the advantage of minimizing side effects and eliminating secondary surgery is unnecessary.

Gel formulations with a high share of the anti-adhesion agent market have limitations in that they are easy to leave the target site due to gravity, but "Lapafilm^®" made in the form of a film has overcome the problem of separation and further strengthened the anti-adhesion effect by acting as a physical barrier.

By improving the attachment and damage between products, which was the limit of existing anti-adhesion films, it is expected that it will not break even if rolled or crumpled during laparoscopic surgery, and can be inserted and attached quickly without a separate instrument, greatly improving the surgical efficiency of medical staff.

"Lapafilm^®" started research and development in 2016 at Mepion, completed exploratory clinical trials in 2022 and therapeutic confirmation clinical trials in 2024, and applied for approval in 2024 and is expected to approve product approval early this year. Mepion was established in 2015 as a specialized company that manufactures high-quality medical devices such as wound cover materials and tissue supplements.

An official from Hyundai Pharmaceutical said, "Lapafilm^® is an innovative product that can drastically reduce the side effects of minimally invasive surgery, and it will greatly improve the quality of life of patients and the efficiency of medical staff's surgery."

Meanwhile, Hyundai Pharmaceutical is a domestic seller of the surgical blockbuster hemostatic agent "Tachosil" and is recognized for its competitiveness in the surgical field based on the abundant experience and know-how accumulated through the sale of "Tachosil" from 2006 to the present.